Syk inhibitor attenuates lupus in FcγRIIb<sup>-</sup><sup>/-</sup> mice through the Inhibition of DNA extracellular traps from macrophages and neutrophils via p38MAPK-dependent pathway.
Ontology highlight
ABSTRACT: Spleen tyrosine kinase (Syk), an important hub of immune signaling, is activated by several signalings in active lupus which could be interfered by Syk inhibitor but is still not completely evaluated in innate immune cells associated with lupus activity. Hence, a Syk inhibitor (fostamatinib; R788) was tested in vivo using Fc gamma receptor-deficient (FcγRIIb-/-) lupus mice and in vitro (macrophages and neutrophils). After 4 weeks of oral Syk inhibitor, 40 week-old FcγRIIb-/- mice (a full-blown lupus model) demonstrated less prominent lupus parameters (serum anti-dsDNA, proteinuria, and glomerulonephritis), systemic inflammation, as evaluated by serum TNFa, IL-6, and citrullinated histone H3 (CitH3), gut permeability defect, as indicated by serum FITC dextran assay, se
SUBMITTER: Sae-Khow K
PROVIDER: S-EPMC11832894 | biostudies-literature | 2025 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA